Navigation Links
Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Date:1/21/2009

Simultaneous Studies to Investigate Novel Therapy for Ulcerative Colitis and Crohn's Disease

OSAKA, Japan, Jan. 22 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") announced today that its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc., has initiated two Phase III clinical trials for vedolizumab (MLN0002), an investigational compound for inflammatory bowel disease (IBD). The trials, known as the GEMINI(TM) program, will study vedolizumab for the treatment of ulcerative colitis and Crohn's disease, the two main types of IBD. Developed by Millennium, vedolizumab is a novel alpha4 beta7 integrin antagonist, a highly selective humanized monoclonal antibody.

"Dosing of the first patient in the Phase III development program of vedolizumab is an exciting milestone," said Brian Feagan, M.D., professor of Medicine at the University of Western Ontario, London, Canada and principal investigator of the GEMINI(TM) studies. "This treatment has great potential to improve the lives of patients with Crohn's disease and ulcerative colitis."

Though current IBD treatments have been effective for many patients with mild to moderate disease, a significant unmet need exists for those patients with moderate to severe IBD. Failure of current medical therapy for ulcerative colitis and Crohn's disease frequently leads to surgical removal of the colon in the case of ulcerative colitis, and multiple bowel resections in the case of Crohn's disease.

If approved by the U.S. Food and Drug Administration (FDA), commercialization of vedolizumab will be the responsibility of Takeda Pharmaceuticals North America, Inc., a subsidiary of Takeda Pharmaceutical Company Limited. Takeda has been a leader in gastroenterological therapies, such as Prevacid(R), for more than 10 years and is committed to bringing new therapies to market that may benefit patients.

"We are excited to a
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
2. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
5. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
6. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
7. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
8. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
9. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
10. Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... its pipeline and new product development efforts. In the ... a Phase 2a study of AZ-002 (Staccato ® ... management of patients with acute repetitive seizures.  Additionally, ... product candidates for development - AZ-008 and AZ-009 ...
(Date:7/31/2014)... Mass. , July 31, 2014  Decision Resources ... technology market intelligence product Marketrack to now include ChinaTrack; ... device landscape in an interactive dashboard providing detailed ... procedure volumes at a hospital level. Other ... , Updated data feed: In addition to end-user surveys ...
(Date:7/31/2014)... 2014 For its innovative modular Biomedical Research ... Art,s-Way Scientific has earned a Modular Building Institute (MBI) ... over 30 categories, MBI,s contest is the commercial modular ... building manufacturers, dealers, and product and service providers. ... capability of our team," said Dan Palmer , ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 2Art's Way Scientific Earns Prestigious Modular Building Institute Award 3Art's Way Scientific Earns Prestigious Modular Building Institute Award 4
... CYBX ) today announced that it will ... Moore, President and Chief Executive Officer, will present at ... on Tuesday, September 21, 2010 at 1:00 PM EDT. ... and by replay at http://cc.talkpoint.com/ubsx001/092110a_lv/?entity=66_7PVQHBG .  The conference ...
... Sept. 13 Xoft, Inc., the pioneer ... minimally-shielded clinical settings, today announced the introduction ... to physicians and distributors in Europe.  The ... to cancer sites with minimal radiation exposure ...
Cached Medicine Technology:Cyberonics to Participate in Upcoming September Investor Conferences 2Xoft Introduces Electronic Brachytherapy Cancer Treatment Platform at ESTRO Meeting 2Xoft Introduces Electronic Brachytherapy Cancer Treatment Platform at ESTRO Meeting 3
(Date:7/31/2014)... Women over the age of 65 face numerous ... greater struggles against poverty and higher rates of asthma ... August issue of Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), outlines the challenges ... practical solutions to improve their care. , ...
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now ... a Systematic Review of Sexual Satisfaction . ... International Journal of Clinical and Health Psychology. , This ... need to have accurate information about sexual satisfaction so ... The material provides a systematic review of 197 ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become especially ... (a medical problem where the airway collapses during sleep and ... rest they need to face their daily challenges. , ... people in the United States alone have sleep apnea. Of ... those treated, many cannot tolerate their prescribed medical device known ...
(Date:7/31/2014)... Vegas, NV (PRWEB) July 31, 2014 Weblify ... Mataka, after 4 years of development and testing. The ... perfectly monetized websites in as little as 5 minutes without ... full Weblify review , Shane Michaels, an SEO expert, ... very quickly. “I’ve seen a lot of web site ...
Breaking Medicine News(10 mins):Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3
... survey suggests that half of doctors in hospital and general practice ... poll of 411 doctors found that 93% of those with worries ... senior colleague or employer. But 10% of GPs and 4% of ... on e in five doctors expressed concerns and even made reference ...
... cause a cancer revolution is available to all Australians. ... ,Pioneered by an Australian, this radiation therapy is ... secondary liver cancer but is expected to be extended ... to patients in clinical trials who could afford the ...
... to a research conducted by Dr. Ute M. Schaefer-Graf ... are less obese. //They say that during pregnancy some ... which results in them having a large baby. But ... child. It was also found that parental obesity and ...
... bogged down with fertility problems can now be hopeful for Dekel ... of a protein //that could have a role, in the placement ... studied the biopsies taken at several stages in the menstrual cycles ... fertility problems, to check if the levels of the protein were ...
... use of particles which are very small. They are ... hazard. // The petition was raised by environmental groups ... strengthen its regulation of sunscreens that contain nano-sized titanium ... cause inflammatory and immune responses in the human body. ...
... by Dr. Michael Thun of the American Cancer Society it was ... women wee less.// On the other hand men who never smoked ... conducted among a million Americans. Lung cancer is by far the ... people this year in the United States alone. ,This ...
Cached Medicine News:Health News:Increase In The Number Of Doctors Reporting About Their Colleagues Abilities 2Health News:A Revolutionary New Treatment For Cancer Available In Australia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: